Table 2 Medications of patients with type 2 diabetes
VFA (cm2) | <100 | ≥100 | p value* | ||
|---|---|---|---|---|---|
SFA (cm2) | <100 (N = 34) | ≥100 (N = 39) | <100 (N = 11) | ≥100 (N = 34) | |
OHA (%) | 41.2 | 33.3 | 54.5 | 54.7 | 0.164 |
Sulfonylureas (%) | 25.0 | 0.0 | 12.5 | 22.4 | 0.055 |
Biguanides (%) | 16.7 | 15.4 | 0.0 | 40.8 | 0.012 |
Alpha-GIs (%) | 25.0 | 0.0 | 12.5 | 10.2 | 0.048 |
TZDs (%) | 8.3 | 0.0 | 7.7 | 6.1 | 0.301 |
DPP4 inhibitors (%) | 25.0 | 42.3 | 62.5 | 34.7 | 0.245 |
Glinides (%) | 8.3 | 0.0 | 0.0 | 0.0 | 0.070 |
GLP-1 agonists (%) | 0.0 | 0.0 | 0.0 | 2.0 | 0.754 |
Insulin (%) | 41.2 | 38.5 | 18.2 | 35.9 | 0.575 |
ACEIs (%) | 0.0 | 5.4 | 0.0 | 3.2 | 0.516 |
ARBs (%) | 17.6 | 24.3 | 45.5 | 44.4 | 0.025 |
CCBs (%) | 11.8 | 5.4 | 36.4 | 30.2 | 0.007 |
Beta blockers (%) | 5.9 | 18.9 | 18.2 | 14.3 | 0.424 |
Alpha blockers (%) | 0.0 | 5.4 | 0.0 | 1.6 | 0.383 |
Diuretics (%) | 5.9 | 24.3 | 9.1 | 11.1 | 0.110 |
Statins (%) | 11.8 | 16.2 | 0.0 | 34.9 | 0.007 |
Fibrates (%) | 0.0 | 0.0 | 0.0 | 3.2 | 0.451 |
UA-lowering agents | 0.0 | 10.8 | 9.1 | 6.3 | 0.289 |
Anti-platelets (%) | 11.8 | 0.0 | 9.1 | 12.7 | 0.168 |